GLP_1 RA Ultrasound Study

NCT06581120 · Enrolling by invitation

Last updated 2026-05-28

This clinical trial is testing whether a GLP-1 receptor agonist affects stomach emptying and aspiration risk in people with diabetes or morbid obesity using ultrasound imaging.

Status Enrolling by invitation Only people invited by the researchers can join.

Type Observational

Participants 100 people Planned (estimated).

Who can join Ages 10–25 · all sexes Healthy volunteers accepted.

Timeline Started 2024-07 · est. completion 2026-07

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06581120 ↗

Description as written by the study sponsor.

The purpose of the study is to determine whether patients taking GLP-1 RAs have increased residual (left behind), gastric (stomach), contents due to delayed gastric emptying when following standard preoperative fasting guidelines.

Treatments tested

Glucagon-Like Peptide-1 receptor agonists Drug

GLP-1 RAs: Glucagon like peptide-1 receptor agonists, this includes patients who are on Liraglutide, Semaglutide, Dulaglutide and Tirzepatide.Tirzepatide which is a combined GLP-1 RA/glucose-dependent insulinotropic polypeptide (GIP) agonist is included as a part of GLP-1 RAs.
Point of Care Gastric Ultrasound also known as POGUS Diagnostic test

A gastric ultrasound following a standard NPO period to determine gastric contents and risk of aspiration during surgery.

Main thing measured	Aspiration Risk determined by POGUS
Sponsor	Children's Hospital Medical Center, Cincinnati
Conditions studied	Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying, Risk of Aspiration, Diabetes, Morbid Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06581120 ↗